Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Gilead has based its entire HIV drug portfolio on updating tenofovir, ostensibly to make it safer for bones and kidneys.
Researchers call for closer cardiovascular monitoring for those switching from the TDF form of the drug to the TAF version.
Biktarvy has a lower rate of adverse health events, according to 96-week data.
Gilead Sciences has released 96-week results from an ongoing double-blinded study comparing the two regimens.
The new single-tablet antiretroviral regimen includes the integrase inhibitor bictegravir and is the smallest such tablet on the market.
The newly approved single-tablet regimen contains the integrase inhibitor bictegravir plus emtricitabine and tenofovir alafenamide.
A new analysis finds that Gilead Sciences’ updated version of its key antiretroviral tenofovir may not actually offer any safety benefits.
Highlights from HIV and hepatitis C research presented at the 2018 Conference on Retroviruses and Opportunistic Infections (CROI) in Boston
Forty-eight-week results are in from a Phase III study that switched participants from Triumeq to Gilead’s new single-tablet regimen.
ViiV alleges that the bictegravir component of the tablet infringes on its own patent for Tivicay (dolutegravir).
The once-daily regimen includes the integrase inhibitor bictegravir plus the contents of Descovy (emtricitabine/tenofovir alafenamide).
A tablet containing bictegravir and the contents of Descovy suppressed HIV as well as boosted protease inhibitor regimens.
The single-tablet regimen includes the experimental bictegravir plus the contents of Descovy (emtricitabine/tenofovir alafenamide).
The investigational integrase inhibitor bictegravir appears to have a resistance profile superior to currently available drugs in its class.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.